科兴制药公告，根据2025年11月17日询价申购情况，初步确定的本次询价转让价格为30.05元/股。本次 询价转让拟转让股份已获全额认购，初步确定受让方为12家机构投资者，拟受让股份总数为1006.28万 股。参与本次询价转让报价及申购的机构投资者家数为24家，涵盖了基金管理公司、合格境外机构投资 者、证券公司、私募基金管理人等专业机构投资者。参与本次询价转让报价及申购的机构投资者合计有 效认购股份数量为1487.7万股，对应的有效认购倍数为1.48倍。 ...

Market Overview - The biopharmaceutical sector experienced a decline of 1.94% on November 17, with Kexing Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3972.03, down 0.46%, while the Shenzhen Component Index closed at 13202.0, down 0.11% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Bohui Innovation: Closed at 8.00, up 2.56% with a trading volume of 824,300 shares [1] - ST Weiming: Closed at 8.31, up 2.21% with a trading volume of 60,800 shares [1] - Major decliners included: - Kexing Pharmaceutical: Closed at 34.59, down 7.88% with a trading volume of 53,300 shares [2] - Jinwei: Closed at 26.05, down 7.06% with a trading volume of 123,100 shares [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 1.211 billion yuan from institutional investors, while retail investors contributed a net inflow of 893 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors increased their positions [2] Individual Stock Capital Flow - Notable capital flows for specific stocks included: - Wanzhe Co.: Net outflow of 37.20 million yuan from institutional investors [3] - Olin Bio: Net inflow of 13.81 million yuan from institutional investors [3] - The data reflects varying levels of investor confidence across different companies within the sector [3]

Market Overview - The A-share market experienced a collective pullback on November 17, with the Shanghai Composite Index closing at 3973.31 points, down 0.43%, while the Shenzhen Component and ChiNext Index fell by 0.35% and 0.8% respectively [1][2]. Trading Volume and Stock Performance - The trading volume in the Shanghai and Shenzhen markets reached 1.27 trillion yuan, an increase of 329 billion yuan compared to the previous trading day. A total of 2337 stocks rose, with 79 hitting the daily limit, while 2960 stocks declined [2]. Lithium Mining Sector - The lithium mining sector showed significant strength, with stocks such as Shengxin Lithium Energy (002240), Rongjie Co. (002192), and Dazhong Mining (001203) all hitting the daily limit of 10%. Shengxin Lithium Energy's year-to-date increase is 160.74% [3][4]. - The National Energy Administration's recent guidance on the development of 100% renewable energy bases and the projected demand for lithium carbonate to grow by 30% by 2026, reaching 1.9 million tons, supports long-term demand for lithium [5]. Cross-Strait Integration Sector - The Fujian Free Trade Zone sector saw a surge, with stocks like Pingtan Development (000592) achieving a remarkable 14 consecutive trading limits. The stock has increased by 255.19% since its rise began on October 17 [6][7]. Aerospace and Defense Sector - The aerospace and defense sector continued to perform well, with companies like Changcheng Aerospace (601606) and Aerospace Development (000547) hitting the daily limit. The sector's strong performance is reflected in the significant year-to-date increases for these stocks [9][10]. AI Application Sector - The AI application sector was notably active, with stocks such as Xuanya International (300612) and Dahua Intelligent (002512) hitting the daily limit. The sector is buoyed by upcoming technological breakthroughs from Huawei in AI [11][13]. Precious Metals and Innovative Pharmaceuticals - The precious metals sector faced declines, with companies like Shengda Resources (000603) and Zhaojin Gold (000506) leading the downturn. The innovative pharmaceuticals sector also saw declines, with stocks like Kexing Pharmaceutical and Kanglong Chemical (300759) dropping over 6% [14][16].

中国经济网北京11月17日讯 科兴制药(688136.SH)11月14日发布股东询价转让计划书。本次拟参与 科兴制药首发前股东询价转让（以下简称"本次询价转让"）的股东为科益医药；出让方拟转让股份的总 数为10,062,800股，占公司总股本的比例为5.00%；本次询价转让为非公开转让，不通过集中竞价交易 方式或大宗交易方式进行，不属于通过二级市场减持。受让方通过询价转让受让的股份，在受让后6个 月内不得转让；本次询价转让的受让方为具备相应定价能力和风险承受能力的机构投资者。 | 拟转让股东 拟转让股份 | | 占总股本 | 占所持股份比例 | 转让原因 | | --- | --- | --- | --- | --- | | 名称 | 数量(股) | 比例 | (截至2025年11月14日) | | | 科益医药 | 10,062,800 | 5.00% | 9.17% | 自身经营发展需要 | 本次询价转让出让方科益医药为公司控股股东，持有公司股份比例超过5%。公司董事长邓学勤通 过科益医药间接持有公司股份。 按照科兴制药11月14日收盘价37.55元计算，科益医药本次询价转让股份对应总市值约3.78亿元。 ...

Policy Developments - The National Health Commission's Director Lei Haichao emphasized the importance of planning for the "14th Five-Year Plan" to accelerate the construction of a healthy China and promote high-quality population development [2] - Key tasks include optimizing the function and layout of medical institutions, implementing strong foundational healthcare projects, and enhancing public health capabilities [2] Pharmaceutical Industry Updates - Bai Cheng Pharmaceutical's subsidiary received clinical trial approval for BIOS2242, a drug for treating acute ischemic stroke, with no current approvals for this product domestically or internationally [5] - Fosun Pharma's subsidiary received FDA approval for HLX11, a biosimilar drug for HER2-positive breast cancer, with applications for registration in China and Europe also accepted [6] Market Movements - Kexing Pharmaceutical's controlling shareholder plans to transfer 5% of its shares through an inquiry-based transfer due to operational needs [8][9] - Enwei Pharmaceutical announced a 20 million yuan investment to establish a fund focused on healthcare and technology sectors, with a total fund size of 201 million yuan [10] Major Industry Events - Guangxi's pharmaceutical exports reached a record high, with a year-on-year increase of 27.23% in the first three quarters of the year [13] - Samsung Medical's subsidiary is a candidate for a procurement project with an estimated value of 168 million yuan, which could positively impact the company's performance [14] Corporate Governance Changes - Haocen Medical announced a change in control, with no single controlling party, following the termination of a cooperation agreement [16] - Yifeng Pharmacy's executives plan to reduce their holdings by a total of 0.0176% of shares due to personal financial needs [17]

Policy Developments - The National Health Commission's Secretary Lei Haichao conducted research in Guangxi, focusing on pediatric and mental health, grassroots medical services, and public hospital reforms, emphasizing the need for a robust health system and high-quality population development [2] - The "14th Five-Year" plan highlights strengthening grassroots healthcare, promoting the distribution of quality medical resources, and enhancing public health capabilities [2] Drug and Medical Device Approvals - Baicheng Pharmaceutical's subsidiary received clinical trial approval for BIOS2242, a treatment for acute ischemic stroke, with no prior approvals for this product globally [5] - Fosun Pharma's subsidiary received FDA approval for HLX11, a biosimilar for HER2-positive breast cancer, with applications pending in China and Europe [6] Capital Market Activities - Kexing Pharmaceutical's controlling shareholder plans to transfer 5% of its shares, citing operational needs, with the transfer process managed by China International Capital Corporation [8] - Enwei Pharmaceutical announced a 20 million yuan investment in a venture capital fund focusing on healthcare and technology, with potential uncertainties regarding returns [10] - Pfizer completed the acquisition of Metsera for $10 billion, a company focused on developing drugs for obesity and cardiovascular diseases [11] Industry Developments - Guangxi's pharmaceutical exports reached a record high, growing 27.23% year-on-year in the first three quarters [13] - Samsung Medical's subsidiary is a candidate for a 168 million yuan procurement project with the State Grid, which could positively impact the company's performance [14] Shareholder Movements - Haocen Medical announced a change in control, with no single controlling party, following a partnership agreement termination [16] - Yifeng Pharmacy executives plan to reduce their holdings by a combined 0.0176% of shares due to personal financial needs [17][18]

近日，科兴制药（688136.SH）引进产品——贝伐珠单抗生物类似药正式获得玻利维亚国家药品与卫生 技术局（AGEMED）批准上市，这是科兴制药与东曜药业合作贝伐珠单抗后获批的第五个国家。 贝伐珠单抗是一款肿瘤治疗领域的常用药物，在全球范围内被用于多种癌症治疗，包括转移性结直肠 癌、晚期/转移性或复发性非小细胞肺癌、复发性胶质母细胞瘤、上皮性卵巢癌、输卵管癌或原发性腹 膜癌以及宫颈癌等，是肿瘤治疗药物中不容忽视的重磅产品。 根据中国医药保健品进出口商会的信息，2024年我国医药产品对东盟、拉丁美洲、非洲等新兴市场出口 额均稳步增长，其中拉丁美洲增长11.4%。拉美新兴医药市场一直以来都是科兴制药重要的商业化区 域，此次玻利维亚获批，将为后续深耕该区域夯实基础。 自今年以来，科兴制药多款出海药物陆续在不同国家获得上市批准。贝伐珠单抗生物类似药已在巴基斯 坦、印尼等5个国家注册获批，目前还有二十多个国家的注册工作正快速推进。科兴制药已在拉美地区 建立子公司，并组建本土化运营团队，未来将对此区域市场精耕细作，为当地的药品可及性贡献力量。 ...

证券代码：688136 证券简称：科兴制药 公告编号：2025-094 科兴生物制药股份有限公司 股东询价转让计划书 股东深圳科益医药控股有限公司（以下简称"科益医药"或"出让方"）保 证向科兴生物制药股份有限公司（以下简称"公司"或"科兴制药"）提供的信 息内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其真实性、准确性 和完整性依法承担法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 1 重要内容提示： 本次拟参与科兴制药首发前股东询价转让（以下简称"本次询价转让"） 的股东为科益医药； 出让方拟转让股份的总数为 10,062,800 股，占公司总股本的比例为 5.00%； 本次询价转让为非公开转让，不通过集中竞价交易方式或大宗交易方式 进行，不属于通过二级市场减持。受让方通过询价转让受让的股份，在受让后 6 个月内不得转让； 本次询价转让的受让方为具备相应定价能力和风险承受能力的机构投资 者。 一、拟参与转让的股东情况 （一）出让方的名称、持股数量、持股比例 出让方委托中国国际金融股份有限公司（以下简称"中金公司"）组织实施 本次询价转让。截至 2025 年 11 月 ...

科兴制药(688136.SH)披露股东询价转让计划书，本次拟参与本次询价转让的股东为科益医药，拟转让 股份的总数为1006.28万股，占公司总股本的比例为5%。 ...

Group 1: Company Announcements - 合富中国's stock price increased by 256.29% over 14 trading days, significantly outperforming the industry and Shanghai Composite Index, leading to a suspension for verification starting November 17 [1] - 工业富联's GB300 achieved mass production in Q3, with improved yield and testing efficiency, positively impacting Q4 gross margin [2] - 天孚通信's controlling shareholder plans to transfer 8.5 million shares, representing 1.09% of total equity, due to personal funding needs [4] - 璞泰来 plans to invest 7.6 billion yuan in a new integrated film coating project, aiming to meet growing demand in the battery and energy storage sectors [5] - 电投能源 intends to acquire 100% of Baiyin Hua Coal Power for 11.149 billion yuan, financing through share issuance and cash [6] - 中微公司 reported that a shareholder completed a reduction of 12.52 million shares, totaling 3.351 billion yuan [7] - 瑞德智能 plans to invest 10 million yuan in a leading company in the power plant robotics sector [8] - 盘古智能 aims to acquire control of a petrochemical company by purchasing 11.97% of its shares for 24.64 million yuan [9] - 泰达股份 signed a memorandum for a waste-to-energy project in Egypt [10] - 杭氧股份 is set to establish a venture capital fund focusing on low-temperature technology and nuclear fusion [11] Group 2: Financial Performance and Regulatory Approvals - 复星医药's subsidiary received FDA approval for a biosimilar drug, with applications pending in China and Europe [21] - 长春高新 received approval for a clinical trial of a new growth hormone drug, with no similar products currently available in China [20] - 海辰药业 obtained a drug registration certificate for a new injection product [22] - 上海机场 reported a 12.46% year-on-year increase in passenger throughput for October [23] Group 3: Shareholder Actions - 深桑达 A plans to publicly transfer 80% of a subsidiary's shares with a minimum price of 1.857 billion yuan [12] - 中电港's major shareholder reduced its stake by 1% between October 31 and November 13 [15] - 康龙化成's major shareholders plan to collectively reduce their holdings by up to 1.5% [16] - 科兴制药's controlling shareholder intends to transfer 5% of its shares [17]